These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 27040861

  • 1. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N, Muratov S, Levine M.
    Clin Invest Med; 2016 Apr 02; 39(2):E48-62. PubMed ID: 27040861
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.
    BMJ; 2012 Mar 12; 344():e1369. PubMed ID: 22411919
    [Abstract] [Full Text] [Related]

  • 3. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
    Farah D, Leme GM, Eliaschewitz FG, Fonseca MCM.
    Diabetes Res Clin Pract; 2019 Mar 12; 149():47-63. PubMed ID: 30710655
    [Abstract] [Full Text] [Related]

  • 4. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT.
    Ann Intern Med; 2015 Nov 03; 163(9):663-72. PubMed ID: 26457538
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM, Cummings DM, Tanenberg RJ.
    Diabetes Res Clin Pract; 2015 Aug 03; 109(2):378-88. PubMed ID: 26059071
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W.
    Diabetes Metab Res Rev; 2014 Mar 03; 30(3):241-56. PubMed ID: 24123720
    [Abstract] [Full Text] [Related]

  • 7. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, Li L, Dudley JT, Johnson KW, Shervey MM, Xu H, Wu Y, Natrajan K, Hripcsak G, Jin P, Van Zandt M, Reckard A, Reich CG, Weaver J, Schuemie MJ, Ryan PB, Callahan A, Shah NH.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181755. PubMed ID: 30646124
    [Abstract] [Full Text] [Related]

  • 8. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J.
    Curr Med Res Opin; 2016 May 03; 32(5):807-16. PubMed ID: 26700585
    [Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P, Lugo-Palacios DG, Carroll O, O'Neill S, Adler AI, Basu A, Silverwood RJ, Bartlett JW, Nitsch D, Charlton P, Briggs AH, Smeeth L, Douglas IJ, Khunti K, Grieve R.
    BMJ; 2024 May 08; 385():e077097. PubMed ID: 38719492
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D, Getnet D, Manyazewal T.
    Sci Rep; 2021 Jan 08; 11(1):137. PubMed ID: 33420333
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    Sharma M, Beckley N, Nazareth I, Petersen I.
    BMJ Open; 2017 Oct 30; 7(10):e017260. PubMed ID: 29084794
    [Abstract] [Full Text] [Related]

  • 12. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R.
    Open Med; 2012 Oct 30; 6(2):e62-74. PubMed ID: 23696771
    [Abstract] [Full Text] [Related]

  • 13. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M, Wang L, Gu L, Yuan W.
    J Diabetes; 2017 Dec 30; 9(12):1107-1117. PubMed ID: 28266136
    [Abstract] [Full Text] [Related]

  • 14. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M.
    Open Med; 2011 Dec 30; 5(1):e35-48. PubMed ID: 22046219
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 30; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C, O' Connor E, Satti MM, Shaw J, Liew A.
    Diabet Med; 2021 Feb 01; 38(2):e14409. PubMed ID: 32979231
    [Abstract] [Full Text] [Related]

  • 18. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X, Wang H, Jing Z, Fu P.
    Curr Med Res Opin; 2014 Sep 01; 30(9):1777-86. PubMed ID: 24805140
    [Abstract] [Full Text] [Related]

  • 19. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May 01; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 20. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH, Yin H, Azoulay L.
    Can J Diabetes; 2015 Oct 01; 39(5):383-9. PubMed ID: 25840943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.